Specifically, 17β-estradiol (E2) inhibits malignancy in HCC through E2/ERβ/MAPK signaling-mediated upregulation of the NLRP3 inflammasome (Wei et al., 2015). This evidence concerns the gene NLRP3 and hepatocellular carcinoma.